{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-054019","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.167572+00:00","generated_at":"2026-05-14T21:11:01.878398+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Allarity Therapeutics CEO to present at Precision Medicine Forum Europe 2026","bullets":["CEO Thomas Jensen will speak on May 11, 2026, in Stockholm, Sweden at Precision Medicine Forum Europe 2026.","Presentation will cover stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and the Stenoparib DRP biomarker.","Allarity is a Phase 2 clinical-stage company developing stenoparib for cancer; no new clinical data or financial results announced.","A corporate presentation furnished as Exhibit 99.1 will be used in investor meetings beginning May 11, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054019","json":"https://secwatch.observer/filing/0001213900-26-054019.json","markdown":"https://secwatch.observer/filing/0001213900-26-054019.md","text":"https://secwatch.observer/filing/0001213900-26-054019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026054019/0001213900-26-054019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026054019/ea0289893-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:11:01.878398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}